Eisai Co Ltd (ESALF) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you very much. financial results. For those of you who are attending in person and those who are virtually attending, please refer to those materials on our website. The presenter is Mr. Haruo Naito, representative corporate officer and CEO. Now, we'd like to begin our presentation on the Q2 results for fiscal year 2024. First, let us share with you the P&L. Revenue grew by 3% year-on-year to reach 385 billion yen. And if you look at the breakdown of the revenue, The pharmaceutical business grew by 5% year-on-year from the previous year. Steady growth was shown. But there were one-time revenue recorded last year in larger amount. Therefore, revenue decreased. In the other business, so at the 67% year-on-year, the gross profit increased by 3% year-on-year. R&D expenses accounted for... The ratio, which was down by one percentage point in terms of ratio to the revenue, of course, while we are making proactive investment in development of our Rekembe business, we have been able to enhance the efficiency in investment in R&D activities. SG&A expenses increased significantly. There were two reasons for the increase, as you see below that. Because of the strong LENVIMA business performance, therefore, there were increased expenses regarding the shared profit of LENVIMA Paid-to-Partner, which increased. And it can be it's still in the midst of being launched into the market. Therefore, due to these, S&G and expenses increased. As a result of this, operating profit was 27.8 billion yen, 87% of the previous year's level. Profit for the period was 21.7 billion yen, which was 94% of the previous year's level. Next. Now, if I look at the breakdown of the revenue migration, the pharmaceutical business... increased by 13.5 billion yen from a year earlier, as you see on the r...